Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-19
2005-07-19
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S213000
Reexamination Certificate
active
06919339
ABSTRACT:
The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.
REFERENCES:
patent: 2937172 (1960-05-01), Shapiro et al.
patent: 3845770 (1974-11-01), Theeuwes
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4892946 (1990-01-01), Levitt
patent: 4902514 (1990-02-01), Barclay et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 5691364 (1997-11-01), Buckman et al.
patent: 6150362 (2000-11-01), Henkin et al.
patent: 12 20 860 (1966-07-01), None
patent: 195 36 891 (1997-04-01), None
patent: 1384684 (1975-02-01), None
patent: WO 81/0320 (1981-10-01), None
patent: WO 00/43369 (2000-07-01), None
patent: WO 01/47897 (2001-07-01), None
Kozakiewicz, Chem. Abstract 130:267406, 1999.
Pomarnacka et al., Chem. Abstract 130:153642, 1998.
Kelarev et al., Chem. Abstract 130:68841, 1998.
Silin et al., Chem. Abstract 129:260428, 1998.
Dollinger et al., Chem. Abstract 270618, 1998.
Hataba, CAPLUS Abstract No. 128:3618, 1997.
Radics et al., CAPLUS Abstract 107:198262, 1987.
Maekawa et al., CAPLUS Abstract 85:154963, 1976.
Watanabe et al., CAPLUS Abstract 132:12332, 1999.
Riebel et al., CAPLUS Abstract 128:282850, 1998.
Lorenz et al., CAPLUS Abstract 127:262706, 1997.
Takematsu et al., CAPLUS Abstract 112:179031, 1990.
Abou-Ouf et al., CAPLUS Abstract 106:4981, 1987.
Shapiro et al., CAOLD Abstract 54:19728f, 1960.
Overberger et al., CAOLD Abstract 49:3980e, 1959.
Walker, et al., “The Adenosine 5′,5′″, P1, P4-Tetraphosphate Receptor Is at the Cell Surface of Heart Cells,”Biochemistry, 32, 14009-14014 (1993).
Smith, et al., Cyclic AMP Induces Apolipoprotein E Binding Activity and Promotes Cholesterol Efflux from a Macrophage Cell Line to Apolipoprotein Acceptors,The Journal of Biological Chemistry, vol. 271, pp. 30647-30655 (1996).
Francis, et al., “Defective Removal of Cellular Cholesterol and Phospholipids by Apolipoprotein A-1 in Tangier Disease,”,J. Clin. Invest., vol. 96, pp. 79-87 (1995).
Oram, et al., “Reduction in Apolipoprotein-mediated Removel of Cellular Lipids by Immortalization of Humans Fibroblasts and its Reversion by cAMP: Lack of Effect with Tangier Disease Cells,”Journal of Lipid Research, vol. 40, pp. 1769-1781 (1999).
Cheung, et al., “Antioxidant Supplements Block the Response of HDL to Simvastatin-Niacin Therapy in Patients With Coronary Artery Disease and Low HDL,”Arterioscler Thromb. Vasc. Biol., 21(8) pp. 1320-26 (2001).
Kirtharides, et al., “Cholesterol Metabolism and Efflux in Human THP-1 Macrophages,”Thrombo Vasc. Biol., 18, pp. 1589-1599 (1998).
Falch, et al., “Substituted Heteroaromatic Anthranilic Acids with Antiinflammatory Activity,”Journal of Medicinal Chemistry, vol. 11, pp. 608-611 (1968).
Ward, et al.., “Irreversible Enzyme Inhibitors 200.1 Active-Site-Directed Inhibitors of Deoxycytidine Kinase”,Journal of Medicinal Chemistry, vol. 20, pp. 88-92 (1977).
Schwartz, et al., “ABC1 Gene Expression and ApoA-1-Medited Cholesterol Efflux are Regulated by LXR”,Biochemical and Biophysical Research Communications, 274, pp. 794-802 (2000).
Chemical Abstracts, vol. 72, no. 13, Abstract No. 67000e, Kuroiki, et al. “Triazine Compounds”, p. 410 (1970).
Chemical Abstracts, vol. 72, no. 13, Abstract No. 66998z, Mueller, et al. “Furylaminotriazines which promote growth of plants”, p. 410 (1970).
Taylor, et al., “The Rearrangement of 5-Nitroso-6-aminopyrimidines to s-Triazines”,J.Am. Chem. Soc., vol. 84, pp. 3744-3748 (1962).
Kuwano, et al., “Synthese von 1,3,5-Triazinen aus Aminosaure-Drivaten”,Argic. Biol.Chem., vol. 35, pp. 1572-1577 (1971).
Gohari, et al., “Studies on s-Triazinyl Aryl/Alkyl Sulphones”,J. Indian Chem. Soc., vol. 53, pp. 207-208 (1976).
Masquelin, et al. “Solution and Solid Phase Synthesis of Combinatorial Libraries of Trisubstituted 1,3,5-Triazines”,Heterocycles, vol. 48, pp. 2489-2506 (1998).
Omokawa, et al., “Phyotoxic Activity of Substitutedα-Methylbenzylamino Derivatives of 2-Chloro (or Methylthio)-4-ethylamino-s-triazines”,Agric. Biol. Chem., vol. 52, pp. 1047-1048 (1988).
Baker, et al., “Puromycin.Synthetic Studies. VI. Analogs of 6-Dimethylaminopurine”,J. Org. Chem., vol. 26, pp. 1793-1801 (1954).
Koppel, et al., “Pyrimidines I. Synthesis of Pyrimidinethiols”,J. Org. Chem., vol. 26, pp. 792-803 (1961).
Asthana, et al., “Synthesis of 9-aryl/pyrimidyl/alkyl-subsituted-(oxy/amino/carbonyl)-acridines and 1,3-bis(9-acridinyl)propan-2-ols as potential anticancer agents”,Indian Journal of Chemistry, vol. 30B, pp. 853-858 (1991).
Okafor, et al., “Studies in the Heterocyclic Series. XVI. Open Azaphenothiazines as New Central Nervous System Depressants”,Chem. Pharm. Bull, vol. 30, pp. 302-318 (1982).
Kelarev, et al., “Synthesis and Properties of sym-Triazine Derivatives”,Chem. Hetercycl. Compd., vol. 23, pp. 1118-1123, (1987).
Podzigun et al., “Chemical Properties of Acylated Derivatives of 4,6-Diamino-2-Mercaptopyrimidine”,Bull. Acad. Sci. USSR Div. Chem. Sci., vol. 29, pp. 1820-1823.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203489, Database-Accession no. 649727, 1962.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203490, Database-Accession nos. 825556, 835148, 1988.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203491, Database-Accession no. 4554677, 1997.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203492, Database-Accessions nos. 847903, 858797, 1988.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main DE: XP002203493, Database-Accession no. 590307, 1988.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203494, Database-Accession nos. 610033, 8260251, 8261917, 8263806, 8264837, 8265543, 8265549, 8265662, 8265677, 8268675, 8274019, 8290516, 1988.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203495, Database-Accession nos. 6869560, 6870711, 6871427, 6872174, 6894394, 1994.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203496, Database-Accession nos. 22301, 37158, 1988.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203497, Database-Accession no. 721058, 1988.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203498, Database-Accession no. 4879840, 1993.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203499, Database-Accession nos. 5571913, 5579402, 1993.
Database Crossfire Beilstein, Online Beilstein Institut zur Foerderung der Wissenschaftern, Frankfurt, am Main, DE: XP002203500 Database-Accession nos. 6410850, 6425583, 6434370, 1994.
Database Chemcats Online, Chemical Abstract Service, Columbus, Ohio, XP002203501, Order Nos.: 0L-567S, 10L-566S, 10L-565S, 10L-561S, 10L-560S, 10L-549S, 10L-525S, 10L-523S, 10L-502S, 2001.
Campbell Michael
Ibrahim Prabha N.
Lawn Richard
Zablocki Jeff A.
CV Theapeutics, Inc.
CV Therapeutics, Inc.
Rao Deepak
LandOfFree
ABCA-1 elevating compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ABCA-1 elevating compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ABCA-1 elevating compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3414858